JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-aventis group’s financial results, that global in-market sales of Copaxone® in the first quarter of 2008 grew by 35% as compared to the first quarter of 2007 and reached a quarterly record of $542 million.
